Compare AbCellera Biologics Inc (ABCL) vs iShares International Treasury Bond ETF (IGOV) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

IGOV trades at $40.75, down 0.71% today, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins. Recent news highlights institutional interest, with DMC Group increasing its stake by 69.5% in Q1 2026, but also notes downside risks from global inflationary pressures affecting its bond holdings.

The outlook remains cautious due to technical bearishness and macroeconomic headwinds, though institutional accumulation may provide some support. Key risks include interest rate sensitivity and geopolitical tensions, warranting close monitoring of earnings and economic indicators for any turnaround signals.